These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 8937349)
1. The CYP2D6B allele is not overrepresented in a population of German patients with idiopathic Parkinson's disease. Gasser T; Müller-Myhsok B; Supala A; Zimmer E; Wieditz G; Wszolek ZK; Vieregge P; Bonifati V; Oertel WH J Neurol Neurosurg Psychiatry; 1996 Nov; 61(5):518-20. PubMed ID: 8937349 [TBL] [Abstract][Full Text] [Related]
2. CYP2D6 is associated with Parkinson's disease but not with dementia with Lewy Bodies or Alzheimer's disease. Atkinson A; Singleton AB; Steward A; Ince PG; Perry RH; McKeith IG; Fairbairn AF; Edwardson JA; Daly AK; Morris CM Pharmacogenetics; 1999 Feb; 9(1):31-5. PubMed ID: 10208640 [TBL] [Abstract][Full Text] [Related]
3. Association between the oxidative polymorphism and early onset of Parkinson's disease. Agúndez JA; Jiménez-Jiménez FJ; Luengo A; Bernal ML; Molina JA; Ayuso L; Vázquez A; Parra J; Duarte J; Coria F Clin Pharmacol Ther; 1995 Mar; 57(3):291-8. PubMed ID: 7697946 [TBL] [Abstract][Full Text] [Related]
4. Case-control study of debrisoquine 4-hydroxylase, N-acetyltransferase 2, and apolipoprotein E gene polymorphisms in Parkinson's disease. Maraganore DM; Farrer MJ; Hardy JA; McDonnell SK; Schaid DJ; Rocca WA Mov Disord; 2000 Jul; 15(4):714-9. PubMed ID: 10928584 [TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphism and Parkinson's disease in Taiwan: study of debrisoquine 4-hydroxylase (CYP2D6). Lo HS; Chen CH; Hogan EL; Kao KP; Wang V; Yan SH J Neurol Sci; 1998 Jun; 158(1):38-42. PubMed ID: 9667775 [TBL] [Abstract][Full Text] [Related]
7. CYP2D6*4 polymorphism is not associated with Parkinson's disease and has no protective role against Alzheimer's disease in the Korean population. Woo SI; Kim JW; Seo HG; Park CH; Han SH; Kim SH; Kim KW; Jhoo JH; Woo JI Psychiatry Clin Neurosci; 2001 Aug; 55(4):373-7. PubMed ID: 11442888 [TBL] [Abstract][Full Text] [Related]
8. No association between familial Alzheimer disease and cytochrome P450 polymorphisms. Yamada H; Dahl ML; Viitanen M; Winblad B; Sjöqvist F; Lannfelt L Alzheimer Dis Assoc Disord; 1998 Sep; 12(3):204-7. PubMed ID: 9772024 [TBL] [Abstract][Full Text] [Related]
9. CYP2D6 gene polymorphism as a probable risk factor for Alzheimer's disease and Parkinson's disease with dementia. Gołab-Janowska M; Honczarenko K; Gawrońska-Szklarz B; Potemkowski A Neurol Neurochir Pol; 2007; 41(2):113-21. PubMed ID: 17530572 [TBL] [Abstract][Full Text] [Related]
10. The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease. Chen X; Xia Y; Alford M; DeTeresa R; Hansen L; Klauber MR; Katzman R; Thal L; Masliah E; Saitoh T Ann Neurol; 1995 Oct; 38(4):653-8. PubMed ID: 7574463 [TBL] [Abstract][Full Text] [Related]
11. No association between CYP2D6 polymorphism and Alzheimer's disease in an Italian population. Scordo MG; Dahl ML; Spina E; Cordici F; Arena MG Pharmacol Res; 2006 Feb; 53(2):162-5. PubMed ID: 16337409 [TBL] [Abstract][Full Text] [Related]
12. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Saitoh T; Xia Y; Chen X; Masliah E; Galasko D; Shults C; Thal LJ; Hansen LA; Katzman R Ann Neurol; 1995 Jan; 37(1):110-2. PubMed ID: 7818242 [TBL] [Abstract][Full Text] [Related]
13. Genotyping of CYP2D6 in Parkinson's disease. Stefanović M; Topić E; Ivanisević AM; Relja M; Korsić M Clin Chem Lab Med; 2000 Sep; 38(9):929-34. PubMed ID: 11097352 [TBL] [Abstract][Full Text] [Related]
14. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Armstrong M; Daly AK; Cholerton S; Bateman DN; Idle JR Lancet; 1992 Apr; 339(8800):1017-8. PubMed ID: 1349052 [TBL] [Abstract][Full Text] [Related]
15. Rarity of debrisoquine hydroxylase gene polymorphism in Chinese patients with Parkinson's disease. Pang CP; Zhang J; Woo J; Chan D; Law LK; Tong SF; Kwok T; Kay R Mov Disord; 1998 May; 13(3):529-32. PubMed ID: 9613747 [TBL] [Abstract][Full Text] [Related]
16. CYP2D6 polymorphism in Parkinson's disease: the Rotterdam Study. Harhangi BS; Oostra BA; Heutink P; van Duijn CM; Hofman A; Breteler MM Mov Disord; 2001 Mar; 16(2):290-3. PubMed ID: 11295783 [TBL] [Abstract][Full Text] [Related]
17. Association of CYP2D microsatellite polymorphism with Lewy body variant of Alzheimer's disease. Tanaka S; Chen X; Xia Y; Kang DE; Matoh N; Sundsmo M; Thomas RG; Katzman R; Thal LJ; Trojanowski JQ; Saitoh T; Ueda K; Masliah E Neurology; 1998 Jun; 50(6):1556-62. PubMed ID: 9633694 [TBL] [Abstract][Full Text] [Related]
18. [Association between the debrisoquine hydroxylase gene polymorphism and the genetic susceptibility of Parkinson's disease]. Tao E; Liu Z; Chen B; Pan X; Shao M Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1998 Oct; 15(5):281-3. PubMed ID: 9758873 [TBL] [Abstract][Full Text] [Related]
19. CYP2D6 allelic frequencies in young-onset Parkinson's disease. Sandy MS; Armstrong M; Tanner CM; Daly AK; Di Monte DA; Langston JW; Idle JR Neurology; 1996 Jul; 47(1):225-30. PubMed ID: 8710083 [TBL] [Abstract][Full Text] [Related]
20. Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B. Kawanishi C; Hanihara T; Maruyama Y; Matsumura T; Onishi H; Inoue K; Sugiyama N; Suzuki K; Yamada Y; Kosaka K Psychiatr Genet; 1997; 7(3):127-9. PubMed ID: 9323326 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]